APO Research
Talk to an analyst

APO RESEARCH · REPORT

First in Class (FIC) Antibody Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Research

First in Class (FIC) Antibody Drugs Industry Research Report 2026

23 December 2025144 pages

Choose your research edition.

Industry ResearchFirst in Class (FIC) Antibody Drugs Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal First in Class (FIC) Antibody Drugs Industry Growth and Trends Forecast to 2032125 pages · $3,450 USDMarket StructureGlobal First in Class (FIC) Antibody Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal First in Class (FIC) Antibody Drugs Market Outlook and Growth Opportunities 2026215 pages · $4,250 USDMarket Analysis & ForecastGlobal First in Class (FIC) Antibody Drugs Market Analysis and Forecast 2026-2032216 pages · $4,950 USD

Market perspective

The global First in Class (FIC) Antibody Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for First in Class (FIC) Antibody Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for First in Class (FIC) Antibody Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for First in Class (FIC) Antibody Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of First in Class (FIC) Antibody Drugs include Suzhou Zejing Biopharmaceutical, Foreseen Biotechnology, Shenzhen Yipusheng, Suzhou Yilian Biopharmaceutical, Beijing Hotgen Biotech, Johnson & Johnson, Lixin Pharmaceutical Technology, Akeso, Inc and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global First in Class (FIC) Antibody Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

First in Class (FIC) Antibody Drugs Market by Company

Suzhou Zejing Biopharmaceutical

Foreseen Biotechnology

Shenzhen Yipusheng

Suzhou Yilian Biopharmaceutical

Beijing Hotgen Biotech

Johnson & Johnson

Lixin Pharmaceutical Technology

Akeso, Inc

Pfizer

Jiangsu Hengrui Medicine

GSK

Shanghai Henlius Biotech, Inc.

Dizal Pharma

AstraZeneca

Vertex Pharmaceuticals

Truqap

Telix

Talvey

Skyclary

Regeneron Pharmaceuticals

Pumis Biotechnology (BioNTech)

Ogsiveo

Merus

Lytgobi

Litfulo

Immatics

Fabhalta

Bicara Therapeutics

Bayer Corporation

Arvinas

First in Class (FIC) Antibody Drugs Segment by Type

Large Molecule FIC Drugs

Small Molecule FIC Drugs

First in Class (FIC) Antibody Drugs Segment by Application

Tumors and Cancers

Nervous System Diseases

Others

First in Class (FIC) Antibody Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global First in Class (FIC) Antibody Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of First in Class (FIC) Antibody Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of First in Class (FIC) Antibody Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of First in Class (FIC) Antibody Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of First in Class (FIC) Antibody Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of First in Class (FIC) Antibody Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global First in Class (FIC) Antibody Drugs Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global First in Class (FIC) Antibody Drugs Sales (k units) of Manufacturers (2021-2026) Table 7. Global First in Class (FIC) Antibody Drugs Sales Market Share by Manufacturers (2021-2026) Table 8. Global First in Class (FIC) Antibody Drugs Revenue of Manufacturers (2021-2026) Table 9. Global First in Class (FIC) Antibody Drugs Revenue Share by Manufacturers (2021-2026) Table 10. Global Market First in Class (FIC) Antibody Drugs Average Price (USD/unit) of Manufacturers (2021-2026) Table 11. Global First in Class (FIC) Antibody Drugs Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of First in Class (FIC) Antibody Drugs, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of First in Class (FIC) Antibody Drugs, Product Type & Application Table 14. Global First in Class (FIC) Antibody Drugs Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global First in Class (FIC) Antibody Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Suzhou Zejing Biopharmaceutical Company Information Table 19. Suzhou Zejing Biopharmaceutical Business Overview Table 20. Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 21. Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drugs Product Portfolio Table 22. Suzhou Zejing Biopharmaceutical Recent Developments Table 23. Foreseen Biotechnology Company Information Table 24. Foreseen Biotechnology Business Overview Table 25. Foreseen Biotechnology First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 26. Foreseen Biotechnology First in Class (FIC) Antibody Drugs Product Portfolio Table 27. Foreseen Biotechnology Recent Developments Table 28. Shenzhen Yipusheng Company Information Table 29. Shenzhen Yipusheng Business Overview Table 30. Shenzhen Yipusheng First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 31. Shenzhen Yipusheng First in Class (FIC) Antibody Drugs Product Portfolio Table 32. Shenzhen Yipusheng Recent Developments Table 33. Suzhou Yilian Biopharmaceutical Company Information Table 34. Suzhou Yilian Biopharmaceutical Business Overview Table 35. Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 36. Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drugs Product Portfolio Table 37. Suzhou Yilian Biopharmaceutical Recent Developments Table 38. Beijing Hotgen Biotech Company Information Table 39. Beijing Hotgen Biotech Business Overview Table 40. Beijing Hotgen Biotech First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 41. Beijing Hotgen Biotech First in Class (FIC) Antibody Drugs Product Portfolio Table 42. Beijing Hotgen Biotech Recent Developments Table 43. Johnson & Johnson Company Information Table 44. Johnson & Johnson Business Overview Table 45. Johnson & Johnson First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 46. Johnson & Johnson First in Class (FIC) Antibody Drugs Product Portfolio Table 47. Johnson & Johnson Recent Developments Table 48. Lixin Pharmaceutical Technology Company Information Table 49. Lixin Pharmaceutical Technology Business Overview Table 50. Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 51. Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drugs Product Portfolio Table 52. Lixin Pharmaceutical Technology Recent Developments Table 53. Akeso, Inc Company Information Table 54. Akeso, Inc Business Overview Table 55. Akeso, Inc First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 56. Akeso, Inc First in Class (FIC) Antibody Drugs Product Portfolio Table 57. Akeso, Inc Recent Developments Table 58. Pfizer Company Information Table 59. Pfizer Business Overview Table 60. Pfizer First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 61. Pfizer First in Class (FIC) Antibody Drugs Product Portfolio Table 62. Pfizer Recent Developments Table 63. Jiangsu Hengrui Medicine Company Information Table 64. Jiangsu Hengrui Medicine Business Overview Table 65. Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 66. Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drugs Product Portfolio Table 67. Jiangsu Hengrui Medicine Recent Developments Table 68. GSK Company Information Table 69. GSK Business Overview Table 70. GSK First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 71. GSK First in Class (FIC) Antibody Drugs Product Portfolio Table 72. GSK Recent Developments Table 73. Shanghai Henlius Biotech, Inc. Company Information Table 74. Shanghai Henlius Biotech, Inc. Business Overview Table 75. Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 76. Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drugs Product Portfolio Table 77. Shanghai Henlius Biotech, Inc. Recent Developments Table 78. Dizal Pharma Company Information Table 79. Dizal Pharma Business Overview Table 80. Dizal Pharma First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 81. Dizal Pharma First in Class (FIC) Antibody Drugs Product Portfolio Table 82. Dizal Pharma Recent Developments Table 83. AstraZeneca Company Information Table 84. AstraZeneca Business Overview Table 85. AstraZeneca First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 86. AstraZeneca First in Class (FIC) Antibody Drugs Product Portfolio Table 87. AstraZeneca Recent Developments Table 88. Vertex Pharmaceuticals Company Information Table 89. Vertex Pharmaceuticals Business Overview Table 90. Vertex Pharmaceuticals First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 91. Vertex Pharmaceuticals First in Class (FIC) Antibody Drugs Product Portfolio Table 92. Vertex Pharmaceuticals Recent Developments Table 93. Truqap Company Information Table 94. Truqap Business Overview Table 95. Truqap First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. Truqap First in Class (FIC) Antibody Drugs Product Portfolio Table 97. Truqap Recent Developments Table 98. Telix Company Information Table 99. Telix Business Overview Table 100. Telix First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 101. Telix First in Class (FIC) Antibody Drugs Product Portfolio Table 102. Telix Recent Developments Table 103. Talvey Company Information Table 104. Talvey Business Overview Table 105. Talvey First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 106. Talvey First in Class (FIC) Antibody Drugs Product Portfolio Table 107. Talvey Recent Developments Table 108. Skyclary Company Information Table 109. Skyclary Business Overview Table 110. Skyclary First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 111. Skyclary First in Class (FIC) Antibody Drugs Product Portfolio Table 112. Skyclary Recent Developments Table 113. Regeneron Pharmaceuticals Company Information Table 114. Regeneron Pharmaceuticals Business Overview Table 115. Regeneron Pharmaceuticals First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 116. Regeneron Pharmaceuticals First in Class (FIC) Antibody Drugs Product Portfolio Table 117. Regeneron Pharmaceuticals Recent Developments Table 118. Pumis Biotechnology (BioNTech) Company Information Table 119. Pumis Biotechnology (BioNTech) Business Overview Table 120. Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 121. Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drugs Product Portfolio Table 122. Pumis Biotechnology (BioNTech) Recent Developments Table 123. Ogsiveo Company Information Table 124. Ogsiveo Business Overview Table 125. Ogsiveo First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 126. Ogsiveo First in Class (FIC) Antibody Drugs Product Portfolio Table 127. Ogsiveo Recent Developments Table 128. Merus Company Information Table 129. Merus Business Overview Table 130. Merus First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 131. Merus First in Class (FIC) Antibody Drugs Product Portfolio Table 132. Merus Recent Developments Table 133. Lytgobi Company Information Table 134. Lytgobi Business Overview Table 135. Lytgobi First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 136. Lytgobi First in Class (FIC) Antibody Drugs Product Portfolio Table 137. Lytgobi Recent Developments Table 138. Litfulo Company Information Table 139. Litfulo Business Overview Table 140. Litfulo First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 141. Litfulo First in Class (FIC) Antibody Drugs Product Portfolio Table 142. Litfulo Recent Developments Table 143. Immatics Company Information Table 144. Immatics Business Overview Table 145. Immatics First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 146. Immatics First in Class (FIC) Antibody Drugs Product Portfolio Table 147. Immatics Recent Developments Table 148. Fabhalta Company Information Table 149. Fabhalta Business Overview Table 150. Fabhalta First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 151. Fabhalta First in Class (FIC) Antibody Drugs Product Portfolio Table 152. Fabhalta Recent Developments Table 153. Bicara Therapeutics Company Information Table 154. Bicara Therapeutics Business Overview Table 155. Bicara Therapeutics First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 156. Bicara Therapeutics First in Class (FIC) Antibody Drugs Product Portfolio Table 157. Bicara Therapeutics Recent Developments Table 158. Bayer Corporation Company Information Table 159. Bayer Corporation Business Overview Table 160. Bayer Corporation First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 161. Bayer Corporation First in Class (FIC) Antibody Drugs Product Portfolio Table 162. Bayer Corporation Recent Developments Table 163. Arvinas Company Information Table 164. Arvinas Business Overview Table 165. Arvinas First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 166. Arvinas First in Class (FIC) Antibody Drugs Product Portfolio Table 167. Arvinas Recent Developments Table 168. Global First in Class (FIC) Antibody Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 169. Global First in Class (FIC) Antibody Drugs Sales by Region (2021-2026) & (k units) Table 170. Global First in Class (FIC) Antibody Drugs Sales Market Share by Region (2021-2026) Table 171. Global First in Class (FIC) Antibody Drugs Sales by Region (2027-2032) & (k units) Table 172. Global First in Class (FIC) Antibody Drugs Sales Market Share by Region (2027-2032) Table 173. Global First in Class (FIC) Antibody Drugs Revenue by Region (2021-2026) & (US$ Million) Table 174. Global First in Class (FIC) Antibody Drugs Revenue Market Share by Region (2021-2026) Table 175. Global First in Class (FIC) Antibody Drugs Revenue by Region (2027-2032) & (US$ Million) Table 176. Global First in Class (FIC) Antibody Drugs Revenue Market Share by Region (2027-2032) Table 177. North America First in Class (FIC) Antibody Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 178. North America First in Class (FIC) Antibody Drugs Sales by Country (2021-2026) & (k units) Table 179. North America First in Class (FIC) Antibody Drugs Sales by Country (2027-2032) & (k units) Table 180. North America First in Class (FIC) Antibody Drugs Revenue by Country (2021-2026) & (US$ Million) Table 181. North America First in Class (FIC) Antibody Drugs Revenue by Country (2027-2032) & (US$ Million) Table 182. Europe First in Class (FIC) Antibody Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 183. Europe First in Class (FIC) Antibody Drugs Sales by Country (2021-2026) & (k units) Table 184. Europe First in Class (FIC) Antibody Drugs Sales by Country (2027-2032) & (k units) Table 185. Europe First in Class (FIC) Antibody Drugs Revenue by Country (2021-2026) & (US$ Million) Table 186. Europe First in Class (FIC) Antibody Drugs Revenue by Country (2027-2032) & (US$ Million) Table 187. Asia Pacific First in Class (FIC) Antibody Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 188. Asia Pacific First in Class (FIC) Antibody Drugs Sales by Country (2021-2026) & (k units) Table 189. Asia Pacific First in Class (FIC) Antibody Drugs Sales by Country (2027-2032) & (k units) Table 190. Asia Pacific First in Class (FIC) Antibody Drugs Revenue by Country (2021-2026) & (US$ Million) Table 191. Asia Pacific First in Class (FIC) Antibody Drugs Revenue by Country (2027-2032) & (US$ Million) Table 192. South America First in Class (FIC) Antibody Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 193. South America First in Class (FIC) Antibody Drugs Sales by Country (2021-2026) & (k units) Table 194. South America First in Class (FIC) Antibody Drugs Sales by Country (2027-2032) & (k units) Table 195. South America First in Class (FIC) Antibody Drugs Revenue by Country (2021-2026) & (US$ Million) Table 196. South America First in Class (FIC) Antibody Drugs Revenue by Country (2027-2032) & (US$ Million) Table 197. Middle East and Africa First in Class (FIC) Antibody Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 198. Middle East and Africa First in Class (FIC) Antibody Drugs Sales by Country (2021-2026) & (k units) Table 199. Middle East and Africa First in Class (FIC) Antibody Drugs Sales by Country (2027-2032) & (k units) Table 200. Middle East and Africa First in Class (FIC) Antibody Drugs Revenue by Country (2021-2026) & (US$ Million) Table 201. Middle East and Africa First in Class (FIC) Antibody Drugs Revenue by Country (2027-2032) & (US$ Million) Table 202. Global First in Class (FIC) Antibody Drugs Sales by Type (2021-2026) & (k units) Table 203. Global First in Class (FIC) Antibody Drugs Sales by Type (2027-2032) & (k units) Table 204. Global First in Class (FIC) Antibody Drugs Sales Market Share by Type (2021-2026) Table 205. Global First in Class (FIC) Antibody Drugs Sales Market Share by Type (2027-2032) Table 206. Global First in Class (FIC) Antibody Drugs Revenue by Type (2021-2026) & (US$ Million) Table 207. Global First in Class (FIC) Antibody Drugs Revenue by Type (2027-2032) & (US$ Million) Table 208. Global First in Class (FIC) Antibody Drugs Revenue Market Share by Type (2021-2026) Table 209. Global First in Class (FIC) Antibody Drugs Revenue Market Share by Type (2027-2032) Table 210. Global First in Class (FIC) Antibody Drugs Price by Type (2021-2026) & (USD/unit) Table 211. Global First in Class (FIC) Antibody Drugs Price by Type (2027-2032) & (USD/unit) Table 212. Global First in Class (FIC) Antibody Drugs Sales by Application (2021-2026) & (k units) Table 213. Global First in Class (FIC) Antibody Drugs Sales by Application (2027-2032) & (k units) Table 214. Global First in Class (FIC) Antibody Drugs Sales Market Share by Application (2021-2026) Table 215. Global First in Class (FIC) Antibody Drugs Sales Market Share by Application (2027-2032) Table 216. Global First in Class (FIC) Antibody Drugs Revenue by Application (2021-2026) & (US$ Million) Table 217. Global First in Class (FIC) Antibody Drugs Revenue by Application (2027-2032) & (US$ Million) Table 218. Global First in Class (FIC) Antibody Drugs Revenue Market Share by Application (2021-2026) Table 219. Global First in Class (FIC) Antibody Drugs Revenue Market Share by Application (2027-2032) Table 220. Global First in Class (FIC) Antibody Drugs Price by Application (2021-2026) & (USD/unit) Table 221. Global First in Class (FIC) Antibody Drugs Price by Application (2027-2032) & (USD/unit) Table 222. Key Raw Materials Table 223. Raw Materials Key Suppliers Table 224. First in Class (FIC) Antibody Drugs Distributors List Table 225. First in Class (FIC) Antibody Drugs Customers List Table 226. First in Class (FIC) Antibody Drugs Industry Trends Table 227. First in Class (FIC) Antibody Drugs Industry Drivers Table 228. First in Class (FIC) Antibody Drugs Industry Restraints Table 229. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. First in Class (FIC) Antibody Drugs Product Image Figure 5. Global First in Class (FIC) Antibody Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global First in Class (FIC) Antibody Drugs Market Size (2021-2032) & (US$ Million) Figure 7. Global First in Class (FIC) Antibody Drugs Sales (2021-2032) & (k units) Figure 8. Global First in Class (FIC) Antibody Drugs Average Price (USD/unit) & (2021-2032) Figure 9. Large Molecule FIC Drugs Product Image Figure 10. Small Molecule FIC Drugs Product Image Figure 11. Tumors and Cancers Product Image Figure 12. Nervous System Diseases Product Image Figure 13. Others Product Image Figure 14. Global First in Class (FIC) Antibody Drugs Revenue Share by Manufacturers in 2025 Figure 15. Global Manufacturers of First in Class (FIC) Antibody Drugs, Manufacturing Sites & Headquarters Figure 16. Global Top 5 and 10 First in Class (FIC) Antibody Drugs Players Market Share by Revenue in 2025 Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global First in Class (FIC) Antibody Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 19. Global First in Class (FIC) Antibody Drugs Sales by Region in 2025 Figure 20. Global First in Class (FIC) Antibody Drugs Revenue by Region in 2025 Figure 21. North America First in Class (FIC) Antibody Drugs Market Size by Country in 2025 Figure 22. North America First in Class (FIC) Antibody Drugs Sales Market Share by Country (2021-2032) Figure 23. North America First in Class (FIC) Antibody Drugs Revenue Market Share by Country (2021-2032) Figure 24. United States First in Class (FIC) Antibody Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Canada First in Class (FIC) Antibody Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Mexico First in Class (FIC) Antibody Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Europe First in Class (FIC) Antibody Drugs Market Size by Country in 2025 Figure 28. Europe First in Class (FIC) Antibody Drugs Sales Market Share by Country (2021-2032) Figure 29. Europe First in Class (FIC) Antibody Drugs Revenue Market Share by Country (2021-2032) Figure 30. Germany First in Class (FIC) Antibody Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. France First in Class (FIC) Antibody Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. U.K. First in Class (FIC) Antibody Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Italy First in Class (FIC) Antibody Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Russia First in Class (FIC) Antibody Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Spain First in Class (FIC) Antibody Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Netherlands First in Class (FIC) Antibody Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Switzerland First in Class (FIC) Antibody Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Sweden First in Class (FIC) Antibody Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Poland First in Class (FIC) Antibody Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Asia Pacific First in Class (FIC) Antibody Drugs Market Size by Country in 2025 Figure 41. Asia Pacific First in Class (FIC) Antibody Drugs Sales Market Share by Country (2021-2032) Figure 42. Asia Pacific First in Class (FIC) Antibody Drugs Revenue Market Share by Country (2021-2032) Figure 43. China First in Class (FIC) Antibody Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Japan First in Class (FIC) Antibody Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. South Korea First in Class (FIC) Antibody Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. India First in Class (FIC) Antibody Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Australia First in Class (FIC) Antibody Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Taiwan First in Class (FIC) Antibody Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia First in Class (FIC) Antibody Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia First in Class (FIC) Antibody Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. South America First in Class (FIC) Antibody Drugs Market Size by Country in 2025 Figure 52. South America First in Class (FIC) Antibody Drugs Sales Market Share by Country (2021-2032) Figure 53. South America First in Class (FIC) Antibody Drugs Revenue Market Share by Country (2021-2032) Figure 54. Brazil First in Class (FIC) Antibody Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Argentina First in Class (FIC) Antibody Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Chile First in Class (FIC) Antibody Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Middle East and Africa First in Class (FIC) Antibody Drugs Market Size by Country in 2025 Figure 58. Middle East and Africa First in Class (FIC) Antibody Drugs Sales Market Share by Country (2021-2032) Figure 59. Middle East and Africa First in Class (FIC) Antibody Drugs Revenue Market Share by Country (2021-2032) Figure 60. Egypt First in Class (FIC) Antibody Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. South Africa First in Class (FIC) Antibody Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Israel First in Class (FIC) Antibody Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Türkiye First in Class (FIC) Antibody Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. GCC Countries First in Class (FIC) Antibody Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Global First in Class (FIC) Antibody Drugs Sales Market Share by Type (2021-2032) Figure 66. Global First in Class (FIC) Antibody Drugs Revenue Market Share by Type (2021-2032) Figure 67. Global First in Class (FIC) Antibody Drugs Price (USD/unit) by Type (2021-2032) Figure 68. Global First in Class (FIC) Antibody Drugs Sales Market Share by Application (2021-2032) Figure 69. Global First in Class (FIC) Antibody Drugs Revenue Market Share by Application (2021-2032) Figure 70. Global First in Class (FIC) Antibody Drugs Price (USD/unit) by Application (2021-2032) Figure 71. First in Class (FIC) Antibody Drugs Value Chain Figure 72. First in Class (FIC) Antibody Drugs Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. First in Class (FIC) Antibody Drugs Industry Opportunities and Challenges

Scope & coverage.

Types
  • Large Molecule FIC Drugs
  • Small Molecule FIC Drugs
Applications
  • Tumors and Cancers
  • Nervous System Diseases
  • Others
Companies covered
  • Suzhou Zejing Biopharmaceutical
  • Foreseen Biotechnology
  • Shenzhen Yipusheng
  • Suzhou Yilian Biopharmaceutical
  • Beijing Hotgen Biotech
  • Johnson & Johnson
  • Lixin Pharmaceutical Technology
  • Akeso, Inc
  • Pfizer
  • Jiangsu Hengrui Medicine
  • GSK
  • Shanghai Henlius Biotech, Inc.
  • Dizal Pharma
  • AstraZeneca
  • Vertex Pharmaceuticals
  • Truqap
  • Telix
  • Talvey
  • Skyclary
  • Regeneron Pharmaceuticals
  • Pumis Biotechnology (BioNTech)
  • Ogsiveo
  • Merus
  • Lytgobi
  • Litfulo
  • Immatics
  • Fabhalta
  • Bicara Therapeutics
  • Bayer Corporation
  • Arvinas

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global First in Class (FIC) Antibody Drugs Market Size (2021-2032)
  4. 2.2.2 Global First in Class (FIC) Antibody Drugs Sales (2021-2032)
  5. 2.2.3 Global First in Class (FIC) Antibody Drugs Market Average Price (2021-2032)
  6. 2.3 First in Class (FIC) Antibody Drugs by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Large Molecule FIC Drugs
  9. 2.3.3 Small Molecule FIC Drugs
  10. 2.4 First in Class (FIC) Antibody Drugs by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Tumors and Cancers
  13. 2.4.3 Nervous System Diseases
  14. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global First in Class (FIC) Antibody Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global First in Class (FIC) Antibody Drugs Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global First in Class (FIC) Antibody Drugs Revenue of Manufacturers (2021-2026)
  4. 3.4 Global First in Class (FIC) Antibody Drugs Average Price by Manufacturers (2021-2026)
  5. 3.5 Global First in Class (FIC) Antibody Drugs Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of First in Class (FIC) Antibody Drugs, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of First in Class (FIC) Antibody Drugs, Product Type & Application
  8. 3.8 Global Manufacturers of First in Class (FIC) Antibody Drugs, Established Date
  9. 3.9 Global First in Class (FIC) Antibody Drugs Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Suzhou Zejing Biopharmaceutical
  2. 4.1.1 Suzhou Zejing Biopharmaceutical Company Information
  3. 4.1.2 Suzhou Zejing Biopharmaceutical Business Overview
  4. 4.1.3 Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drugs Product Portfolio
  6. 4.1.5 Suzhou Zejing Biopharmaceutical Recent Developments
  7. 4.2 Foreseen Biotechnology
  8. 4.2.1 Foreseen Biotechnology Company Information
  9. 4.2.2 Foreseen Biotechnology Business Overview
  10. 4.2.3 Foreseen Biotechnology First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Foreseen Biotechnology First in Class (FIC) Antibody Drugs Product Portfolio
  12. 4.2.5 Foreseen Biotechnology Recent Developments
  13. 4.3 Shenzhen Yipusheng
  14. 4.3.1 Shenzhen Yipusheng Company Information
  15. 4.3.2 Shenzhen Yipusheng Business Overview
  16. 4.3.3 Shenzhen Yipusheng First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Shenzhen Yipusheng First in Class (FIC) Antibody Drugs Product Portfolio
  18. 4.3.5 Shenzhen Yipusheng Recent Developments
  19. 4.4 Suzhou Yilian Biopharmaceutical
  20. 4.4.1 Suzhou Yilian Biopharmaceutical Company Information
  21. 4.4.2 Suzhou Yilian Biopharmaceutical Business Overview
  22. 4.4.3 Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drugs Product Portfolio
  24. 4.4.5 Suzhou Yilian Biopharmaceutical Recent Developments
  25. 4.5 Beijing Hotgen Biotech
  26. 4.5.1 Beijing Hotgen Biotech Company Information
  27. 4.5.2 Beijing Hotgen Biotech Business Overview
  28. 4.5.3 Beijing Hotgen Biotech First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Beijing Hotgen Biotech First in Class (FIC) Antibody Drugs Product Portfolio
  30. 4.5.5 Beijing Hotgen Biotech Recent Developments
  31. 4.6 Johnson & Johnson
  32. 4.6.1 Johnson & Johnson Company Information
  33. 4.6.2 Johnson & Johnson Business Overview
  34. 4.6.3 Johnson & Johnson First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Johnson & Johnson First in Class (FIC) Antibody Drugs Product Portfolio
  36. 4.6.5 Johnson & Johnson Recent Developments
  37. 4.7 Lixin Pharmaceutical Technology
  38. 4.7.1 Lixin Pharmaceutical Technology Company Information
  39. 4.7.2 Lixin Pharmaceutical Technology Business Overview
  40. 4.7.3 Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drugs Product Portfolio
  42. 4.7.5 Lixin Pharmaceutical Technology Recent Developments
  43. 4.8 Akeso, Inc
  44. 4.8.1 Akeso, Inc Company Information
  45. 4.8.2 Akeso, Inc Business Overview
  46. 4.8.3 Akeso, Inc First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Akeso, Inc First in Class (FIC) Antibody Drugs Product Portfolio
  48. 4.8.5 Akeso, Inc Recent Developments
  49. 4.9 Pfizer
  50. 4.9.1 Pfizer Company Information
  51. 4.9.2 Pfizer Business Overview
  52. 4.9.3 Pfizer First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Pfizer First in Class (FIC) Antibody Drugs Product Portfolio
  54. 4.9.5 Pfizer Recent Developments
  55. 4.10 Jiangsu Hengrui Medicine
  56. 4.10.1 Jiangsu Hengrui Medicine Company Information
  57. 4.10.2 Jiangsu Hengrui Medicine Business Overview
  58. 4.10.3 Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drugs Product Portfolio
  60. 4.10.5 Jiangsu Hengrui Medicine Recent Developments
  61. 4.11 GSK
  62. 4.11.1 GSK Company Information
  63. 4.11.2 GSK Business Overview
  64. 4.11.3 GSK First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 GSK First in Class (FIC) Antibody Drugs Product Portfolio
  66. 4.11.5 GSK Recent Developments
  67. 4.12 Shanghai Henlius Biotech, Inc.
  68. 4.12.1 Shanghai Henlius Biotech, Inc. Company Information
  69. 4.12.2 Shanghai Henlius Biotech, Inc. Business Overview
  70. 4.12.3 Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drugs Product Portfolio
  72. 4.12.5 Shanghai Henlius Biotech, Inc. Recent Developments
  73. 4.13 Dizal Pharma
  74. 4.13.1 Dizal Pharma Company Information
  75. 4.13.2 Dizal Pharma Business Overview
  76. 4.13.3 Dizal Pharma First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Dizal Pharma First in Class (FIC) Antibody Drugs Product Portfolio
  78. 4.13.5 Dizal Pharma Recent Developments
  79. 4.14 AstraZeneca
  80. 4.14.1 AstraZeneca Company Information
  81. 4.14.2 AstraZeneca Business Overview
  82. 4.14.3 AstraZeneca First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 AstraZeneca First in Class (FIC) Antibody Drugs Product Portfolio
  84. 4.14.5 AstraZeneca Recent Developments
  85. 4.15 Vertex Pharmaceuticals
  86. 4.15.1 Vertex Pharmaceuticals Company Information
  87. 4.15.2 Vertex Pharmaceuticals Business Overview
  88. 4.15.3 Vertex Pharmaceuticals First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Vertex Pharmaceuticals First in Class (FIC) Antibody Drugs Product Portfolio
  90. 4.15.5 Vertex Pharmaceuticals Recent Developments
  91. 4.16 Truqap
  92. 4.16.1 Truqap Company Information
  93. 4.16.2 Truqap Business Overview
  94. 4.16.3 Truqap First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Truqap First in Class (FIC) Antibody Drugs Product Portfolio
  96. 4.16.5 Truqap Recent Developments
  97. 4.17 Telix
  98. 4.17.1 Telix Company Information
  99. 4.17.2 Telix Business Overview
  100. 4.17.3 Telix First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Telix First in Class (FIC) Antibody Drugs Product Portfolio
  102. 4.17.5 Telix Recent Developments
  103. 4.18 Talvey
  104. 4.18.1 Talvey Company Information
  105. 4.18.2 Talvey Business Overview
  106. 4.18.3 Talvey First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Talvey First in Class (FIC) Antibody Drugs Product Portfolio
  108. 4.18.5 Talvey Recent Developments
  109. 4.19 Skyclary
  110. 4.19.1 Skyclary Company Information
  111. 4.19.2 Skyclary Business Overview
  112. 4.19.3 Skyclary First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Skyclary First in Class (FIC) Antibody Drugs Product Portfolio
  114. 4.19.5 Skyclary Recent Developments
  115. 4.20 Regeneron Pharmaceuticals
  116. 4.20.1 Regeneron Pharmaceuticals Company Information
  117. 4.20.2 Regeneron Pharmaceuticals Business Overview
  118. 4.20.3 Regeneron Pharmaceuticals First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  119. 4.20.4 Regeneron Pharmaceuticals First in Class (FIC) Antibody Drugs Product Portfolio
  120. 4.20.5 Regeneron Pharmaceuticals Recent Developments
  121. 4.21 Pumis Biotechnology (BioNTech)
  122. 4.21.1 Pumis Biotechnology (BioNTech) Company Information
  123. 4.21.2 Pumis Biotechnology (BioNTech) Business Overview
  124. 4.21.3 Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  125. 4.21.4 Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drugs Product Portfolio
  126. 4.21.5 Pumis Biotechnology (BioNTech) Recent Developments
  127. 4.22 Ogsiveo
  128. 4.22.1 Ogsiveo Company Information
  129. 4.22.2 Ogsiveo Business Overview
  130. 4.22.3 Ogsiveo First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  131. 4.22.4 Ogsiveo First in Class (FIC) Antibody Drugs Product Portfolio
  132. 4.22.5 Ogsiveo Recent Developments
  133. 4.23 Merus
  134. 4.23.1 Merus Company Information
  135. 4.23.2 Merus Business Overview
  136. 4.23.3 Merus First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  137. 4.23.4 Merus First in Class (FIC) Antibody Drugs Product Portfolio
  138. 4.23.5 Merus Recent Developments
  139. 4.24 Lytgobi
  140. 4.24.1 Lytgobi Company Information
  141. 4.24.2 Lytgobi Business Overview
  142. 4.24.3 Lytgobi First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  143. 4.24.4 Lytgobi First in Class (FIC) Antibody Drugs Product Portfolio
  144. 4.24.5 Lytgobi Recent Developments
  145. 4.25 Litfulo
  146. 4.25.1 Litfulo Company Information
  147. 4.25.2 Litfulo Business Overview
  148. 4.25.3 Litfulo First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  149. 4.25.4 Litfulo First in Class (FIC) Antibody Drugs Product Portfolio
  150. 4.25.5 Litfulo Recent Developments
  151. 4.26 Immatics
  152. 4.26.1 Immatics Company Information
  153. 4.26.2 Immatics Business Overview
  154. 4.26.3 Immatics First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  155. 4.26.4 Immatics First in Class (FIC) Antibody Drugs Product Portfolio
  156. 4.26.5 Immatics Recent Developments
  157. 4.27 Fabhalta
  158. 4.27.1 Fabhalta Company Information
  159. 4.27.2 Fabhalta Business Overview
  160. 4.27.3 Fabhalta First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  161. 4.27.4 Fabhalta First in Class (FIC) Antibody Drugs Product Portfolio
  162. 4.27.5 Fabhalta Recent Developments
  163. 4.28 Bicara Therapeutics
  164. 4.28.1 Bicara Therapeutics Company Information
  165. 4.28.2 Bicara Therapeutics Business Overview
  166. 4.28.3 Bicara Therapeutics First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  167. 4.28.4 Bicara Therapeutics First in Class (FIC) Antibody Drugs Product Portfolio
  168. 4.28.5 Bicara Therapeutics Recent Developments
  169. 4.29 Bayer Corporation
  170. 4.29.1 Bayer Corporation Company Information
  171. 4.29.2 Bayer Corporation Business Overview
  172. 4.29.3 Bayer Corporation First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  173. 4.29.4 Bayer Corporation First in Class (FIC) Antibody Drugs Product Portfolio
  174. 4.29.5 Bayer Corporation Recent Developments
  175. 4.30 Arvinas
  176. 4.30.1 Arvinas Company Information
  177. 4.30.2 Arvinas Business Overview
  178. 4.30.3 Arvinas First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  179. 4.30.4 Arvinas First in Class (FIC) Antibody Drugs Product Portfolio
  180. 4.30.5 Arvinas Recent Developments
5 Global First in Class (FIC) Antibody Drugs Market Scenario by Region
  1. 5.1 Global First in Class (FIC) Antibody Drugs Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global First in Class (FIC) Antibody Drugs Sales by Region: 2021-2032
  3. 5.2.1 Global First in Class (FIC) Antibody Drugs Sales by Region: 2021-2026
  4. 5.2.2 Global First in Class (FIC) Antibody Drugs Sales by Region: 2027-2032
  5. 5.3 Global First in Class (FIC) Antibody Drugs Revenue by Region: 2021-2032
  6. 5.3.1 Global First in Class (FIC) Antibody Drugs Revenue by Region: 2021-2026
  7. 5.3.2 Global First in Class (FIC) Antibody Drugs Revenue by Region: 2027-2032
  8. 5.4 North America First in Class (FIC) Antibody Drugs Market Facts & Figures by Country
  9. 5.4.1 North America First in Class (FIC) Antibody Drugs Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America First in Class (FIC) Antibody Drugs Sales by Country (2021-2032)
  11. 5.4.3 North America First in Class (FIC) Antibody Drugs Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe First in Class (FIC) Antibody Drugs Market Facts & Figures by Country
  16. 5.5.1 Europe First in Class (FIC) Antibody Drugs Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe First in Class (FIC) Antibody Drugs Sales by Country (2021-2032)
  18. 5.5.3 Europe First in Class (FIC) Antibody Drugs Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific First in Class (FIC) Antibody Drugs Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific First in Class (FIC) Antibody Drugs Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific First in Class (FIC) Antibody Drugs Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific First in Class (FIC) Antibody Drugs Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America First in Class (FIC) Antibody Drugs Market Facts & Figures by Country
  41. 5.7.1 South America First in Class (FIC) Antibody Drugs Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America First in Class (FIC) Antibody Drugs Sales by Country (2021-2032)
  43. 5.7.3 South America First in Class (FIC) Antibody Drugs Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa First in Class (FIC) Antibody Drugs Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa First in Class (FIC) Antibody Drugs Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa First in Class (FIC) Antibody Drugs Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa First in Class (FIC) Antibody Drugs Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global First in Class (FIC) Antibody Drugs Sales by Type (2021-2032)
  2. 6.1.1 Global First in Class (FIC) Antibody Drugs Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global First in Class (FIC) Antibody Drugs Sales Market Share by Type (2021-2032)
  4. 6.2 Global First in Class (FIC) Antibody Drugs Revenue by Type (2021-2032)
  5. 6.2.1 Global First in Class (FIC) Antibody Drugs Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global First in Class (FIC) Antibody Drugs Revenue Market Share by Type (2021-2032)
  7. 6.3 Global First in Class (FIC) Antibody Drugs Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global First in Class (FIC) Antibody Drugs Sales by Application (2021-2032)
  2. 7.1.1 Global First in Class (FIC) Antibody Drugs Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global First in Class (FIC) Antibody Drugs Sales Market Share by Application (2021-2032)
  4. 7.2 Global First in Class (FIC) Antibody Drugs Revenue by Application (2021-2032)
  5. 7.2.1 Global First in Class (FIC) Antibody Drugs Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global First in Class (FIC) Antibody Drugs Revenue Market Share by Application (2021-2032)
  7. 7.3 Global First in Class (FIC) Antibody Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 First in Class (FIC) Antibody Drugs Value Chain Analysis
  2. 8.1.1 First in Class (FIC) Antibody Drugs Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 First in Class (FIC) Antibody Drugs Production Mode & Process
  5. 8.2 First in Class (FIC) Antibody Drugs Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 First in Class (FIC) Antibody Drugs Distributors
  8. 8.2.3 First in Class (FIC) Antibody Drugs Customers
9 Global First in Class (FIC) Antibody Drugs Analyzing Market Dynamics
  1. 9.1 First in Class (FIC) Antibody Drugs Industry Trends
  2. 9.2 First in Class (FIC) Antibody Drugs Industry Drivers
  3. 9.3 First in Class (FIC) Antibody Drugs Industry Opportunities and Challenges
  4. 9.4 First in Class (FIC) Antibody Drugs Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst